blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3890776

EP3890776 - RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  10.09.2021
Database last updated on 03.09.2024
FormerThe international publication has been made
Status updated on  13.06.2020
Most recent event   Tooltip10.08.2024Change - representative 
Applicant(s)For all designated states
International AIDS Vaccine Initiative
125 Broad Street, 9th Floor
New York, NY 10004 / US
For all designated states
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037 / US
[2024/26]
Former [2021/41]For all designated states
International AIDS Vaccine Initiative
125 Broad Street, 9th Floor
New York, NY 10004 / US
For all designated states
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037 / US
For all designated states
Burton, Dennis, R.
C/o the Scripps Research Institute
10550 North Torrey Pines Road
La Jolla CA 92037 / US
For all designated states
Andrabi, Raiees
C/o International AIDS Vaccine Initiative
125 Broad Street 9th Floor
New York NY 10004 / US
Inventor(s)01 / BURTON, Dennis, R.
c/o The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037 / US
02 / ANDRABI, Raiees
c/o International AIDS Vaccine Initiative
125 Broad Street, 9th Floor
New York, NY 10004 / US
 [2021/41]
Representative(s)Buzzi, Notaro & Antonielli d'Oulx S.p.A.
Corso Vittorio Emmanuele II, 6
10123 Torino / IT
[N/P]
Former [2021/41]Freyria Fava, Cristina
Buzzi, Notaro & Antonielli d'Oulx S.p.A.
Corso Vittorio Emanuele ll, 6
10123 Torino / IT
Application number, filing date19892591.903.12.2019
[2021/41]
WO2019US64138
Priority number, dateUS201862774693P03.12.2018         Original published format: US 201862774693 P
[2021/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020117740
Date:11.06.2020
Language:EN
[2020/24]
Type: A1 Application with search report 
No.:EP3890776
Date:13.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 11.06.2020 takes the place of the publication of the European patent application.
[2021/41]
Search report(s)International search report - published on:US11.06.2020
(Supplementary) European search report - dispatched on:EP30.11.2022
ClassificationIPC:A61K39/21
[2021/41]
CPC:
A61K39/12 (EP); A61P31/18 (EP); A61K2039/545 (EP);
A61K2039/55577 (EP); A61K2039/575 (EP); A61K2039/70 (EP);
C12N2740/16122 (EP); C12N2740/16134 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/41]
TitleGerman:REKOMBINANTE HIV-ENV-POLYPEPTIDE UND IHRE VERWENDUNGEN[2021/41]
English:RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES[2021/41]
French:POLYPEPTIDES D'ENVELOPPE DU VIH RECOMBINÉS ET LEURS UTILISATIONS[2021/41]
Entry into regional phase01.07.2021National basic fee paid 
01.07.2021Search fee paid 
01.07.2021Designation fee(s) paid 
01.07.2021Examination fee paid 
Examination procedure03.06.2021Observations by third parties
01.07.2021Examination requested  [2021/41]
23.06.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
16.12.2021Renewal fee patent year 03
27.12.2022Renewal fee patent year 04
27.12.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2011109511  (INT AIDS VACCINE INITIATIVE [US], et al) [X] 1,9,10,14 * figure 9c; claims 1,4 * [I] 12,13,15;
 [XI]WO2013039792  (US HEALTH [US], et al) [X] 1-3,8-10 * page 40, line 33 - line 36 * * page 41, line 18 - line 29; table 1; sequence 8 * [I] 12-15;
 [XI]WO2014043220  (UNIV CALIFORNIA [US]) [X] 1-3,8-10 * claims 1, 9; sequence 16 * [I] 12-15;
 [X]WO2016037154  (US HEALTH [US]) [X] 1-3,5,7,12-15 * claims 1, 3, 6; sequence 745 *;
 [XI]WO2017023857  (UNIV CALIFORNIA [US]) [X] 1-3,8-10 * figure 3 * [I] 12-15;
 [XI]  - JAMES E. VOSS ET AL, "Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model", CELL REPORTS, US, (20171001), vol. 21, no. 1, doi:10.1016/j.celrep.2017.09.024, ISSN 2211-1247, pages 222 - 235, XP055635632 [X] 1,5,7 * page 222, column right * * page 224, column right * * page 225, column left * [I] 12-15

DOI:   http://dx.doi.org/10.1016/j.celrep.2017.09.024
 [A]  - ANDRABI RAIEES ET AL, "Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design", IMMUNITY, CELL PRESS, AMSTERDAM, NL, (20151119), vol. 43, no. 5, doi:10.1016/J.IMMUNI.2015.10.014, ISSN 1074-7613, pages 959 - 973, XP029301066 [A] 1-3,5,7-10,12-15 * Summary *

DOI:   http://dx.doi.org/10.1016/j.immuni.2015.10.014
 [A]  - ROGIER W. SANDERS ET AL, "A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies", PLOS PATHOGENS, (20130919), vol. 9, no. 9, doi:10.1371/journal.ppat.1003618, page e1003618, XP055131150 [A] 1-3,5,7-10,12-15 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.ppat.1003618
International search[XY]  - CROOKS et al., "Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation", PLoS Pathog, (20180502), vol. 14, no. 5, pages 1 - 39, XP55714848 [X] 2, 12-14 * . Entire document, especially abstract; p. 2, para 1; p. 4, col 6; p. 17, col 1-3; p. 28, col 1; p. 32, col 3 * [Y] 1, 3

DOI:   http://dx.doi.org/10.1371/journal.ppat.1007024
 [Y]  - VOSS et al., "Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model", Cell Reports, (20171003), vol. 21, no. 1, doi:10.1016/j.celrep.2017.09.024, pages 222 - 235, XP055635632 [Y] 1, 3 * . Entire document, especially abstract; p. 231, col 2 to p. 232, col 1, para 1 *

DOI:   http://dx.doi.org/10.1016/j.celrep.2017.09.024
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.